A 3D in-vitro biomimicking Caco-2 intestinal permeability model-based assessment of physically modified telmisartan towards an alkalizer-free formulation development
European Journal of Pharmaceutics and Biopharmaceutics · 2024
DOI: 10.1016/j.ejpb.2024.114480 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2024. Verfasst von Sunil Kumar Sah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal 700054, India. Hauptthemen laut MEDLINE: Telmisartan, Solubility, Permeability, Particle Size. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 71 Literaturangaben.
Abstract (Originalsprache)
Efficient telmisartan delivery for hypertension management requires the incorporation of meglumine and/or sodium hydroxide as an alkalizer in the formulation. Long-term use of powerful alkalis with formulation as part of chronic therapy can cause metabolic alkalosis, ulcers, diarrhea, and body pain. Here, we aimed to design a telmisartan formulation without alkalizers. Telmisartan properties were tailor-made by microfluidizer-based physical modification. After microfluidization, telmisartan nanosuspension was lyophilized to obtain telmisartan premix powder. The optimized telmisartan nanosuspension had an average particle size of 579.85 ± 32.14 nm. The lyophilized premix was characterized by FT-IR, DSC, and PXRD analysis to ensure its physicochemical characteristics. The solubility analysis of premix showed 2.2 times, 2.3 times, and 6 times solubility improvement in 0.1 N HCl, phosphate buffer pH 7.5, and pH 6.8 compared to pure telmisartan. A 3D in-vitro Caco-2 model was developed to compare apparent permeability of API and powder premix. It showed that the powder premix was more permeable than pure API. The tablet formulation prepared from the telmisartan premix showed a dissolution profile comparable to that of the marketed formulation. The technique present herein can be used as a platform technology for solubility and permeability improvement of similar classes of molecules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal 700054, India.
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal 700054, India.
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal 700054, India.
- Department of Natural Products, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal 700054, India.
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal 700054, India. Electronic address: subhadeep@niperkolkata.ac.in.
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal 700054, India. Electronic address: santanu.kaity@niperkolkata.ac.in.
Zitieren
APA
Sah, S. K., Alam, K., Kumari, M., Malootty, R., Nath, S., Ravichandiran, V., Roy, S., & Kaity, S. (2024). A 3D in-vitro biomimicking Caco-2 intestinal permeability model-based assessment of physically modified telmisartan towards an alkalizer-free formulation development. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2024.114480
Vancouver
Sah SK, Alam K, Kumari M, Malootty R, Nath S, Ravichandiran V, et al. A 3D in-vitro biomimicking Caco-2 intestinal permeability model-based assessment of physically modified telmisartan towards an alkalizer-free formulation development. European Journal of Pharmaceutics and Biopharmaceutics. 2024. doi:10.1016/j.ejpb.2024.114480
BibTeX
@article{Sah2024,
author = {Sah, Sunil Kumar and Alam, Kamare and Kumari, Mamta and Malootty, R and Nath, Subham and Ravichandiran, Velayutham and Roy, Subhadeep and Kaity, Santanu},
title = {A 3D in-vitro biomimicking Caco-2 intestinal permeability model-based assessment of physically modified telmisartan towards an alkalizer-free formulation development},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2024},
doi = {10.1016/j.ejpb.2024.114480}
}
EUVIMED